Highlights: NovoCure Limited

  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses: NovoCure Limited

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • With an enterprise value anticipated at 3.53 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings Chart: NovoCure Limited

Source: Surperformance

ESG chart: NovoCure Limited

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
10.25B
5.23B
- 4.88B
- 4.86B
- 4.69B
4.46B
Average 5.73B
Weighted average by Cap.
See all sector ratings
Investor
-
Trader
ESG MSCI
A

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health
-

Valuation

P/E ratio
-
EV/REVENUE
EV/EBITDA
-
PBR
-
Yield
-

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. Ratings NovoCure Limited